爱尔眼科
Search documents
医疗服务板块1月6日涨1.58%,三博脑科领涨,主力资金净流出4028.92万元
Zheng Xing Xing Ye Ri Bao· 2026-01-06 09:00
从资金流向上来看,当日医疗服务板块主力资金净流出4028.92万元,游资资金净流出1.62亿元,散户资 金净流入2.02亿元。医疗服务板块个股资金流向见下表: | 代码 | 名称 | 主力净流入 (元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 603259 | 药明康德 | 1.80 Z | 4.07% | 1.01亿 | 2.28% | -2.81 Z | -6.35% | | 301293 | 三博脑科 | 9474.34万 | 31.32% | -5881.76万 | -19.44% | -3592.59万 | -11.88% | | 002173 | 创新医疗 | 7708.81万 | 56.37% | -3382.60万 | -24.74% | -4326.21万 | -31.64% | | 300015 | 爱尔眼科 | 7521.51万 | 7.12% | -1571.23万 | -1.49% | -5950.28万 | -5.63% ...
网络大V恶意诽谤爱尔眼科医生,被判1年半
Xin Lang Cai Jing· 2026-01-06 05:22
Core Viewpoint - The case of Dr. Li Jianhua against Chen, a social media influencer, highlights the judicial protection of citizens' reputation rights and aligns with the national effort to strengthen online governance and punish online crimes [1][9]. Group 1: Background of the Case - Chen, who had no prior connection to Dr. Li, began a campaign of online harassment against him following a medical dispute involving another party, resulting in over two years of defamation through social media [2][10]. - The defamatory statements included accusations of "academic fraud" and "practicing medicine without a license," leading to severe personal and professional consequences for Dr. Li, including mental health issues and disruption of the hospital's operations [2][10]. Group 2: Legal Proceedings - After unsuccessful attempts to resolve the issue amicably, Dr. Li filed a civil lawsuit in November 2021, which resulted in a court ruling against Chen for defamation, requiring him to delete the defamatory content and issue an apology [3][11]. - Despite the civil judgment, Chen continued to spread false information, further damaging Dr. Li's reputation and undermining public trust in the judicial system [3][11]. Group 3: Criminal Charges and Sentencing - Dr. Li subsequently pursued criminal charges against Chen, leading to a conviction for defamation, with the court determining that Chen's actions met the legal criteria for severe circumstances, including high engagement metrics on his defamatory posts [5][14]. - The court sentenced Chen to 18 months in prison, emphasizing the importance of upholding legal standards in online discourse and the consequences of violating others' rights [6][14]. Group 4: Implications for Online Governance - This case serves as a significant precedent in the fight against online defamation and reinforces the message that the internet is not a lawless space, urging citizens to respect legal boundaries while exercising their freedom of expression [7][15]. - The ongoing efforts by the government to enhance online governance, including the implementation of new laws and regulations, aim to create a safer digital environment and reduce instances of online violence and defamation [6][15].
ETF盘中资讯|脑机接口迎政策技术双催化,三博脑科、美好医疗20CM两连板!全市场规模最大医疗ETF(512170)20日新高!
Jin Rong Jie· 2026-01-06 02:17
Core Viewpoint - The medical ETF (512170) has shown significant performance, with a daily increase of over 5% and reaching a 20-day high, indicating strong market interest and potential growth in the healthcare sector [1]. Group 1: ETF Performance - The medical ETF opened high on January 6 and saw a peak increase of over 1%, with a trading volume exceeding 350 million yuan [1]. - The ETF has recorded five consecutive days of gains, reflecting a robust upward trend in the healthcare sector [1]. Group 2: Component Stocks - Brain-computer interface stocks, specifically Sanbo Brain Science and Meihua Medical, both hit the daily limit up of 20%, marking two consecutive days of gains [1]. - Conversely, the CXO sector experienced a pullback, with Tigermed seeing a decline of over 1% [1]. Group 3: Market Insights - Tesla CEO Elon Musk announced that Neuralink plans to start large-scale production of brain-computer interface devices in 2026, which could accelerate the commercialization of this technology [2]. - The National Medical Products Administration of China held a meeting to expedite the review and approval of related medical devices, indicating regulatory support for the industry [2]. Group 4: Industry Outlook - CITIC Securities highlighted that China's brain-computer interface technology is relatively advanced globally, which may lead to the emergence of leading companies in this field and enhance valuations in the secondary market [3]. - Zhongtai Securities noted a potential rebound in the pharmaceutical sector after four years of decline, driven by the realization of innovative drug export logic and industry recovery due to policy reforms [3].
脑机接口迎政策技术双催化,三博脑科、美好医疗20CM两连板!全市场规模最大医疗ETF(512170)20日新高!
Xin Lang Cai Jing· 2026-01-06 02:01
Group 1 - The medical ETF (512170) opened high on January 6, rising over 1% and reaching a 20-day high, with real-time transaction volume exceeding 350 million yuan. The ETF recorded a daily increase of over 5%, marking five consecutive days of gains [1][5] - Brain-computer interface stocks, including Sanbo Brain Science and Meihua Medical, both hit the 20% daily limit up, achieving two consecutive boards. Conversely, the CXO sector saw a pullback, with Tigermed falling over 1% [1][5] Group 2 - On January 5, 2026, Elon Musk announced that Neuralink plans to start large-scale production of brain-computer interface devices, advancing the commercialization of the technology. Concurrently, the National Medical Products Administration held a meeting to expedite the review and approval of related medical devices [3][6] - According to CITIC Securities, China's brain-computer interface technology is relatively advanced globally, with potential to cultivate leading companies in the sector. This could enhance the valuations of related listed companies in the secondary market and stimulate financing in the primary market, creating a synergy between capital and industry development [7] - Zhongtai Securities noted that the pharmaceutical sector is expected to rebound in 2025 after four consecutive years of decline, driven by the realization of innovative drug export logic and industry recovery post-policy reform. Certain areas of the medical device sector may also see a reversal of difficulties [7]
12国外籍人才长沙考察交流,共绘国际人才社区建设新蓝图
Chang Sha Wan Bao· 2026-01-05 15:55
长沙晚报掌上长沙1月5日讯(全媒体记者 徐运源 通讯员 张唯)新年伊始,暖意融融。为深化国际人才交流合 作,全方位展现长沙优质人才发展生态,加速推进国际人才社区建设提质增效,1月5日,一场集政策解读、平台 考察与文化体验于一体的外籍人才考察交流活动在望城区成功举办。本次活动由市委组织部(市委人才办)指 导,市科技局主办,市对外科技合作交流中心、望城区协办,吸引来自12个国家的多名外籍人才代表携随行人员 参与。 活动以"现场观摩感知发展活力,工作推进共融城市未来"为核心,首站聚焦望城大泽湖·海归小镇这一海外人才集 聚高地。在海归小镇展示中心,考察团系统了解了小镇的规划布局、产业定位及全链条人才服务配套体系,对长 沙为海外人才量身打造的创新创业平台有了具象认知。随后,在研发中心天空之厅举行的长沙国际人才社区建设 推进会暨大泽湖国际人才社区启动式上,相关负责人深度解读了长沙国际人才社区建设的政策框架、发展目标与 重点任务。 务实暖心的政策举措、清晰明确的发展蓝图,让外籍人才切实感受到长沙集聚国际人才的决心与诚意,现场不少 代表主动交流对接,表达了深化合作的强烈意愿。 "长沙人才济济,工作生活品质高,这里的人们都充满 ...
网络大V恶意诽谤爱尔眼科医生,法院判实刑
Xin Lang Cai Jing· 2026-01-05 09:36
Core Viewpoint - The case of Dr. Li Jianhua from Guangzhou Aier Eye Hospital against online influencer Chen Mou for defamation highlights the importance of protecting citizens' reputation rights and reflects the government's ongoing efforts to strengthen online governance and punish cyber crimes [1][5]. Group 1: Case Background - Dr. Li Jianhua was subjected to online harassment by Chen Mou, who began spreading defamatory statements about him on social media after a medical dispute involving another party [1]. - Chen Mou published hundreds to thousands of defamatory posts from July 2021, falsely accusing Dr. Li of "academic fraud" and "practicing medicine without a license," leading to severe personal and professional consequences for Dr. Li [1][2]. Group 2: Legal Proceedings - After unsuccessful attempts to resolve the issue amicably, Dr. Li filed a civil lawsuit in November 2021, which resulted in court rulings against Chen Mou for infringing on Dr. Li's reputation and image rights [2][3]. - Despite the civil court's decisions, Chen Mou continued to spread false information, further damaging Dr. Li's reputation and undermining public trust in the judicial system [2]. Group 3: Criminal Charges and Sentencing - Dr. Li decided to pursue criminal charges against Chen Mou, leading to a conviction for defamation, with the court finding that Chen Mou's actions met the criteria for serious defamation as defined by legal standards [4][5]. - The court sentenced Chen Mou to one and a half years in prison, emphasizing the severity of his actions and the need for accountability in online spaces [5]. Group 4: Implications for Online Governance - This case serves as a significant precedent in combating online defamation and reinforces the message that the internet is not a lawless space, urging citizens to respect the legal boundaries of free speech [6]. - The Chinese government has been actively enhancing online governance through various laws and regulations aimed at curbing online infringement and violence, with new laws set to take effect in 2026 to further address these issues [5][6].
医疗服务板块1月5日涨4.77%,三博脑科领涨,主力资金净流入10.28亿元
Zheng Xing Xing Ye Ri Bao· 2026-01-05 09:09
Core Insights - The medical services sector experienced a significant increase of 4.77% on January 5, with Sanbo Brain Science leading the gains [1] - The Shanghai Composite Index closed at 4023.42, up 1.38%, while the Shenzhen Component Index closed at 13828.63, up 2.24% [1] Medical Services Sector Performance - Sanbo Brain Science (301293) closed at 70.78, with a rise of 20.01% and a trading volume of 106,700 shares, amounting to a transaction value of 755 million [1] - Likang Life (300143) saw a closing price of 11.38, increasing by 15.18% with a trading volume of 473,200 shares, totaling 518 million [1] - Chengdu Xian Dao (688222) closed at 26.14, up 11.47%, with a trading volume of 277,100 shares, resulting in a transaction value of 704 million [1] - Other notable performers include She Nei Medical (301060) at 10.20 (+10.27%), International Medical (000516) at 4.72 (+10.02%), and Zhaoyan New Drug (603127) at 38.51 (+10.00%) [1] Capital Flow Analysis - The medical services sector saw a net inflow of 1.028 billion from institutional investors, while retail investors contributed a net inflow of 174 million [2] - Notable net inflows from institutional investors include Zhaoyan New Drug (603127) with 235 million and Sanbo Brain Science (301293) with 214 million [3] - Conversely, retail investors showed significant outflows from several stocks, including Sanbo Brain Science (301293) with a net outflow of 136 million and Likang Life (300143) with 27.9 million [3]
上市公司掌门人筹谋“十五五” 铿锵向未来
Zheng Quan Shi Bao Wang· 2026-01-05 00:39
Group 1 - BYD aims to maintain significant R&D and financial investment to consolidate electrification and promote intelligence in the new "15th Five-Year Plan" period [3] - The company plans to integrate global resources for collaborative innovation and accelerate its global industrial layout to build a world-class Chinese brand [3] - BYD's annual sales have achieved a tenfold growth during the "14th Five-Year Plan" period, establishing it as the largest electric vehicle manufacturer globally [3] Group 2 - Oriental Fortune emphasizes the importance of empowering the real economy and serving people's needs in the financial sector during the "15th Five-Year Plan" [5] - The company aims to leverage technology to connect wealth management and financing needs effectively [5] Group 3 - Moore Threads focuses on accelerating the application of domestic GPUs across various industries to support digital transformation [7] - The company has established a complete technology stack based on a unified architecture, achieving a systematic closed loop from hardware to application [7] Group 4 - Muyuan Foods is committed to producing safe and healthy pork products, aiming for high-quality development in the pig farming industry [9] - The company plans to leverage technology to address industry challenges and contribute to the high-quality development of China's pig farming sector [9] Group 5 - Zhongwei Company aims to achieve 50% to 60% market coverage in high-end semiconductor equipment through organic growth and external expansion [12] - The company emphasizes the importance of technological innovation and industry chain collaboration to enhance global competitiveness [12] Group 6 - Huayou Cobalt plans to align its strategy with national planning during the "15th Five-Year Plan" period, focusing on creating customer value and leading industry development [16] - The company aims to become a leading technology enterprise in energy materials globally [16] Group 7 - Aier Eye Hospital integrates clinical services, research innovation, and public health education into a comprehensive eye health ecosystem [18] - The company is committed to advancing AI diagnostics and expanding its eye health service network [18] Group 8 - Tianci Materials focuses on sustainable development principles, enhancing innovation capabilities in lithium-ion battery materials and specialty chemicals [20] - The company aims to embrace a new growth cycle in the lithium and energy storage industry over the next five years [20] Group 9 - JinkoSolar emphasizes technological innovation as the core driver of its development, aiming to enhance the efficiency of photovoltaic applications [22] - The company is focused on integrating advanced technologies with traditional manufacturing to foster new productive forces [22] Group 10 - Jishi Media aims to integrate cultural and technological advancements, focusing on digital transformation and innovation in the media sector [24] - The company plans to enhance its competitiveness by focusing on AI, data elements, and low-altitude economy [24] Group 11 - China National Machinery Industry Corporation aims to transform into a technology-driven engineering company while embedding its development into the national modernization blueprint [26] - The company plans to enhance its efficiency and investment value through capital market engagement and focus on green engineering and digital infrastructure [26]
上市公司掌门人筹谋“十五五” 铿锵向未来
证券时报· 2026-01-05 00:25
Core Viewpoint - The article emphasizes the strategic plans and aspirations of various companies as they embark on the "15th Five-Year Plan" period, highlighting their commitment to innovation, technology, and global competitiveness. Group 1: BYD - BYD aims to maintain significant R&D and financial investment to solidify its position in electrification and promote smart technology, leveraging global resources for innovation [4] - The company has achieved a tenfold increase in annual sales during the "14th Five-Year Plan" and seeks to capitalize on the global expansion of Chinese brands [4] Group 2: Oriental Fortune - Oriental Fortune expresses confidence in the resilience of the Chinese economy and emphasizes the importance of financial technology in connecting wealth management with real economy financing [6] - The company aims to serve diverse stakeholders and enhance its role in the financial transformation landscape [6] Group 3: Moore Threads - Moore Threads focuses on accelerating the application of domestic GPUs across various industries, contributing to the digital transformation [8] - The company has established a comprehensive technology stack and aims to maintain high R&D investment to strengthen its competitive edge [8] Group 4: Muyuan Foods - Muyuan Foods is committed to producing safe and healthy pork products, responding to consumer demand while advancing the pig farming industry towards high-quality development [10] - The company plans to leverage technology to address industry challenges and enhance overall quality [10] Group 5: Zhongwei Company - Zhongwei Company aims to achieve 50% to 60% market coverage in high-end semiconductor equipment through organic growth and expansion over the next five to ten years [12] - The company emphasizes collaboration within the industry to enhance global competitiveness [12] Group 6: AVIC Shenyang Aircraft - AVIC Shenyang Aircraft is focused on achieving significant milestones in the "15th Five-Year Plan" by enhancing core functions and competitiveness [14] - The company aims to contribute to the construction of a strong aviation nation through strategic initiatives [14] Group 7: Huayou Cobalt - Huayou Cobalt plans to align its strategy with national planning during the "15th Five-Year Plan," focusing on creating customer value and leading industry development [16] - The company aims to become a leading technology enterprise in energy materials [16] Group 8: Aier Eye Hospital - Aier Eye Hospital integrates its development with national strategies, focusing on innovation in eye health services and technology [18] - The company aims to enhance its service network and collaborate with partners to improve public health outcomes [18] Group 9: Tinci Materials - Tinci Materials is committed to sustainable development through innovation in lithium-ion battery materials and specialty chemicals [21] - The company anticipates a new growth cycle in the lithium and energy storage industries over the next five years [21] Group 10: JinkoSolar - JinkoSolar emphasizes technology innovation as a core driver for its development, focusing on high-efficiency solar cell technologies [23] - The company aims to integrate advanced technologies with traditional manufacturing to foster new productive capabilities [23] Group 11: Jishi Media - Jishi Media aims to integrate cultural and technological advancements, focusing on becoming a leading cultural technology enterprise [25] - The company plans to leverage AI and digital transformation to enhance its service offerings [25] Group 12: China National Machinery Industry Corporation - China National Machinery Industry Corporation is focused on deepening its role in China's modernization efforts while enhancing its international competitiveness [27] - The company aims to foster new productive capabilities in emerging sectors such as green engineering and digital infrastructure [27]
爱尔眼科创始人、董事长陈邦:以初心守光明 以创新赴新程
Zheng Quan Shi Bao· 2026-01-04 17:37
爱尔眼科愿与各方同心聚力,"以初心守光明,以创新赴新程",在"十五五"航程中勇攀医学高峰,为健康中国注入 持久动能! 时序更替,华章启新。新的一年,我谨代表爱尔眼科,向长期信赖支持我们的社会各界致以最真挚的祝福! 站在"十五五"规划开局之年的关键节点,爱尔眼科始终将企业发展融入国家战略,积极践行上市公司的责任与担 当。我们坚信,眼健康事业不是临床诊疗的"孤岛",而是串联临床服务、科研创新、产业链协同与公众健康教育 的全生命周期眼健康生态。 新岁启封,征程再拓。2026年,我们将紧扣"十五五"规划建议部署,坚持推进"创新驱动科技爱尔"战略:创新路 上,让AI诊疗、前沿技术跨越山海惠及群众;责任路上,完善覆盖城乡的眼健康服务网络;协同路上,携手伙伴 共享成果,彰显中国眼科的国际竞争力。 ...